August 19, 2021 News by Marta Figueiredo, PhD MediciNova Planning Phase 3 Trial of Oral Ibudilast for SPMS MediciNovaĀ is planning to launch a Phase 3 clinical trial that will evaluate its investigational oral candidate ibudilast (MN-166) in people with secondary progressive multiple sclerosis (SPMS) without relapses. The company is actively engaging with potential partners that could help fund the study. āOver the past quarter, we…
November 12, 2020 News by Forest Ray PhD Non-invasive Imaging Technique Reveals Ibudilast’s Neuroprotective Effect A non-invasive retina imaging technique known as optical coherence tomography (OCT) provided evidence of the neuroprotective effect of ibudilastĀ (MN-166) ā an oral medication designed to reduce the body’s inflammatory responses āĀ in people with progressive forms of multiple sclerosis (MS). The data also…
July 17, 2019 News by Ana Pena PhD Phase 3 Trial of Ibudilast Planned for SPMS Patients with Inactive Disease, MediciNova Says A Phase 3 trial is planned to confirm the safety and efficacy of oral ibudilast (MN-166) in treating people with secondary progressive multiple sclerosis (SPMS) without relapses, or those whose disease is not active, MediciNovaĀ announced. Data from this single Phase 3 study may be used to request…
September 1, 2017 News by Patricia Silva, PhD #MSParis2017 – MediciNova to Share Results of Ibudilast Trial in Progressive MS at October Summit MediciNova will present data from its clinical trial of ibudilast (MN-166) in progressive multiple sclerosis (MS) at the upcoming 7th Joint ECTRIMS – ACTRIMS Meeting in Paris. The European and American Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS and ACTRIMS) selected the presentation “…
December 22, 2016 News by Patricia Silva, PhD Use of Ibudilast as MS Treatment Shows Enough Promise to Continue Trial Ibudilast (MN-166) has shown enough promise as a treatment for progressive multiple sclerosis (MS) that its U.S.Ā Phase 2b trial (NCT01982942) should continue, the U.S. National Institute of Health’s Data and Safety Monitoring Board has recommended. A key goal of the 96-week trial is to determine whether ibudilast canĀ slow the…
July 19, 2016 News by Patricia Silva, PhD 127 Progressive MS Patients Finish Treatment in Phase 2 Study of Ibudilast, MediciNova Reports MediciNova recently reported that half of the 255 patients enrolled in a Phase 2b clinical trialĀ (SPRINT-MS) exploring MN-166 (ibudilast) in progressive multiple sclerosis (MS) had completed the 96-week-long treatment. Interim data will be analyzed by the trialās external Data Safety Monitoring Board later this year, with results…
July 19, 2016 News by Patricia Silva, PhD 127 Progressive MS Patients Finish Treatment in Phase 2 Study of Ibudilast, MediciNova Reports MediciNova recently reported that half of the 255 patients enrolled in a Phase 2b clinical trialĀ (SPRINT-MS) exploring MN-166 (ibudilast) in progressive multiple sclerosis (MS) had completed the 96-week-long treatment. Interim data will be analyzed by the trialās external Data Safety Monitoring Board later this year, with results…
March 23, 2016 News by Patricia Silva, PhD Potential Progressive MS Treatment, Ibudilast, Approved for Fast Track Development by FDA MediciNova, Inc.,Ā announced that MN-166 (ibudilast) has been approved for “fast track” development byĀ the U.S. Food and Drug Administration (FDA)Ā as a potentialĀ treatment forĀ progressive multiple sclerosis (MS).Ā Progressive MS includesĀ both the primary progressive (PPMS) and secondary progressive (SPMS) forms of the disease. MediciNovaās MN-166 was licensed from Kyorin Pharmaceuticals for its potential…
June 15, 2015 News by Patricia Silva, PhD MediciNova Announces Update On Phase 2b Trial of MN-166 (Ibudilast) Involving 255 Progressive MS Patients MediciNova, Inc., a biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the ongoing clinical trial of MN-166 (ibudilast) in patients with progressive multiple sclerosis (progressive MS) has finished the randomization of 255 patients, exceeding the…
May 13, 2015 News by Patricia Silva, PhD Major Progressive MS Trial Completes Enrollment For Experimental Therapy While multiple sclerosis (MS) is consideredĀ a rare condition with majorĀ unmet medical needs, the treatments for progressive forms of MS are evenĀ scarcer, with no viable, FDA-approved drugs available to specifically addressĀ these forms of the disease. Because of this, the MS community is eagerly followingĀ a major…
May 8, 2015 News by Patricia Silva, PhD MediciNova Completes Enrollment for Phase 2b Study of Experimental Progressive Multiple Sclerosis Treatment MediciNova, Inc., a publicly-traded biopharmaceutical company developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the National Institute of Neurological Disorders and Stroke (NINDS) notified the company of full enrollment of theirĀ ongoing clinical study evaluating ibudilastĀ (MN-166) for the treatment of progressive…
February 4, 2015 News by admin MediciNova To Present on Multiple Sclerosis Therapy at American Academy of Neurology 67th Annual Meeting MediciNova, Inc., has announcedĀ the acceptance ofĀ an abstractĀ describing their ongoing Phase 2b clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (MS). The poster is to be presented at the American Academy of Neurology (AAN) 67th Annual Meeting, April 18 – 25, 2015 in Washington, DC. The presentation is titled…
September 24, 2014 News by Maureen Newman Primary, Secondary Progressive MS Therapy to be Tested in Phase 2 Trial by MediciNova MediciNova, Inc., recently announced that it had surpassed 50% enrollment for the phase 2b clinical trial evaluating MN-166 (ibudilast) in progressive multiple sclerosis patients. As of September 15th, 150 of an expected 250 patients have enrolled for treatment, and the trial is on track to complete enrollment by the…